Overview

Expect more industry consolidation, counsels Morningstar’s Healthcare Observer report. Find out why and learn what role the challenging reimbursement environment plays. Morningstar identified a few potential deals. It notes, for instance, that BioMarin’s focus on rare diseases and gene therapies–and expected financial growth–make it a logical acquisition target. But for whom? Find out what Damien Conover, Morningstar’s director, pharmaceuticals, predicts. Meanwhile, learn which companies could be acquisition targets for Pfizer, and gain insights into why Conover doesn’t believe Pfizer CEO Albert Bourla’s insistence it plans to eschew dealmaking in favor of growing organically.